C.I. MedicalLtd Zukünftiges Wachstum

Future Kriterienprüfungen 5/6

C.I. MedicalLtd wird ein jährliches Gewinn- und Umsatzwachstum von 23.5% bzw. 11.7% prognostiziert. Der Gewinn pro Aktie wird voraussichtlich wachsen um 23.5% pro Jahr. Die Eigenkapitalrendite wird in 3 Jahren voraussichtlich 12.7% betragen.

Wichtige Informationen

31.9%

Wachstumsrate der Gewinne

31.9%

EPS-Wachstumsrate

Healthcare Gewinnwachstum	9.7%
Wachstumsrate der Einnahmen	28.5%
Zukünftige Eigenkapitalrendite	14.5%
Analystenabdeckung	Low
Zuletzt aktualisiert	28 Aug 2024

Jüngste Aktualisierungen zum künftigen Wachstum

Recent updates

Introducing C.I. MedicalLtd (TYO:3540), The Stock That Zoomed 114% In The Last Year

Feb 18

Should You Be Adding C.I. MedicalLtd (TYO:3540) To Your Watchlist Today?

Jan 31

Can C.I. MedicalLtd (TYO:3540) Keep Up These Impressive Returns?

Jan 13

Could The Market Be Wrong About C.I. Medical Co.,Ltd. (TYO:3540) Given Its Attractive Financial Prospects?

Dec 26

Is C.I. Medical Co.,Ltd. (TYO:3540) Potentially Undervalued?

Dec 08

Can You Imagine How Jubilant C.I. MedicalLtd's (TYO:3540) Shareholders Feel About Its 118% Share Price Gain?

Nov 20

Gewinn- und Umsatzwachstumsprognosen

TSE:3540 - Zukünftige Analystenschätzungen und Finanzdaten der Vergangenheit (JPY Millions)
Datum	Umsatz	Gewinne	Freier Cashflow	Bargeld aus operativen Tätigkeiten	Durchschn. Anz. Analysten
12/31/2026	106,000	3,700	N/A	4,950	1
12/31/2025	98,000	3,000	N/A	5,400	1
12/31/2024	70,700	2,400	N/A	-8,344	1
6/30/2024	47,747	1,433	-6,585	2,933	N/A
3/31/2024	46,575	1,808	N/A	N/A	N/A
12/31/2023	45,628	2,082	-9,086	-156	N/A
9/30/2023	45,071	2,162	N/A	N/A	N/A
6/30/2023	44,125	2,219	-4,594	1,090	N/A
3/31/2023	43,473	2,173	N/A	N/A	N/A
12/31/2022	42,891	2,521	-7,939	1,409	N/A
9/30/2022	42,073	2,709	N/A	N/A	N/A
6/30/2022	41,754	2,798	-4,720	2,077	N/A
3/31/2022	41,142	2,815	N/A	N/A	N/A
12/31/2021	41,205	2,820	-1,253	1,578	N/A
9/30/2021	41,500	3,182	N/A	N/A	N/A
6/30/2021	40,833	3,334	4,083	4,497	N/A
3/31/2021	39,593	3,309	N/A	N/A	N/A
12/31/2020	37,393	2,920	3,701	4,159	N/A
9/30/2020	33,251	2,263	N/A	N/A	N/A
6/30/2020	31,964	1,924	211	473	N/A
3/31/2020	30,265	1,608	N/A	N/A	N/A
12/31/2019	28,763	1,505	1,144	1,402	N/A
9/30/2019	28,876	1,571	N/A	N/A	N/A
6/30/2019	26,898	1,345	613	1,127	N/A
3/31/2019	26,484	1,414	N/A	N/A	N/A
12/31/2018	25,806	1,329	212	722	N/A
9/30/2018	24,892	1,358	N/A	N/A	N/A
6/30/2018	24,323	1,458	1,340	1,579	N/A
3/31/2018	23,336	1,445	N/A	N/A	N/A
12/31/2017	22,830	1,539	N/A	1,006	N/A
9/30/2017	21,999	1,486	N/A	N/A	N/A
6/30/2017	21,440	1,497	N/A	491	N/A
3/31/2017	20,887	1,390	N/A	781	N/A
12/31/2016	20,334	1,282	N/A	1,071	N/A
12/31/2015	18,145	1,088	N/A	N/A	N/A
12/31/2014	16,084	901	N/A	N/A	N/A

Analystenprognosen zum zukünftigen Wachstum

Einkommen vs. Sparrate: 3540Das prognostizierte Gewinnwachstum (23.5% pro Jahr) liegt über der Sparquote (0.2%).

Ertrag vs. Markt: 3540Die Erträge des Unternehmens (23.5% pro Jahr) werden voraussichtlich schneller wachsen als der Markt JP (8.4% pro Jahr).

Hohe Wachstumserträge: 3540Es wird erwartet, dass die Erträge des Unternehmens in den nächsten 3 Jahren erheblich steigen werden.

Einnahmen vs. Markt: 3540Die Einnahmen des Unternehmens (11.7% pro Jahr) werden voraussichtlich schneller wachsen als der Markt JP (3.9% pro Jahr).

Hohe Wachstumseinnahmen: 3540Die Einnahmen des Unternehmens (28.5% pro Jahr) werden voraussichtlich schneller wachsen als 20% pro Jahr.

Wachstumsprognosen für den Gewinn je Aktie

Künftige Eigenkapitalrendite

Künftige Eigenkapitalrendite: 3540Die Eigenkapitalrendite des Unternehmens wird in 3 Jahren voraussichtlich niedrig sein (12.7 %).

C.I. MedicalLtd Zukünftiges Wachstum

Future Kriterienprüfungen 5/6

Wichtige Informationen

Jüngste Aktualisierungen zum künftigen Wachstum

Consensus EPS estimates fall by 16%, revenue upgraded

Price target decreased to JP¥4,300

Price target decreased to JP¥5,300

Analysts increase EPS estimates to JP¥320

Analysts increase EPS estimates to JP¥251

Recent updates

New minor risk - Profit margin trend

Second quarter 2024 earnings released

C.I. Medical Co.,Ltd. (TSE:3540) Looks Just Right With A 25% Price Jump

Investor sentiment improves as stock rises 36%

New minor risk - Share price stability

New minor risk - Dividend sustainability

Investor sentiment improves as stock rises 20%

C.I. Medical Co.,Ltd. to Report Q2, 2024 Results on Aug 13, 2024

First quarter 2024 earnings released: EPS: JP¥24.70 (vs JP¥52.11 in 1Q 2023)

C.I. Medical Co.,Ltd. (TSE:3540) signed sale and purchase agreement to acquire Nissen Holdings Co., Ltd. from Seven & i Net Media Co., Ltd. for ¥4.1 billion.

C.I. Medical Co.,Ltd. (TSE:3540) signed sale and purchase agreement to acquire Nissen Holdings Co., Ltd. from Seven & i Net Media Co., Ltd. for ¥4.1 billion.

C.I. Medical Co.,Ltd., Annual General Meeting, Mar 26, 2024

Full year 2023 earnings released: EPS: JP¥208 (vs JP¥252 in FY 2022)

C.I. Medical Co.,Ltd. to Report Fiscal Year 2023 Results on Feb 13, 2024

Upcoming dividend of JP¥25.00 per share at 0.6% yield

Investor sentiment improves as stock rises 15%

New major risk - Financial position

Third quarter 2023 earnings released: EPS: JP¥51.29 (vs JP¥57.01 in 3Q 2022)

C.I. Medical Co.,Ltd. to Report Q3, 2023 Results on Nov 14, 2023

New major risk - Earnings quality

Second quarter 2023 earnings released: EPS: JP¥70.50 (vs JP¥65.91 in 2Q 2022)

C.I. Medical Co.,Ltd. to Report Q2, 2023 Results on Aug 08, 2023

First quarter 2023 earnings released: EPS: JP¥52.10 (vs JP¥86.91 in 1Q 2022)

Full year 2022 earnings: EPS misses analyst expectations

Now 23% undervalued after recent price drop

Consensus EPS estimates fall by 16%, revenue upgraded

Full year 2022 earnings: EPS misses analyst expectations

C.I. Medical Co.,Ltd. to Report Fiscal Year 2022 Results on Feb 14, 2023

Upcoming dividend of JP¥28.50 per share

Third quarter 2022 earnings released: EPS: JP¥57.01 (vs JP¥65.91 in 3Q 2021)

Third quarter 2022 earnings released: EPS: JP¥56.99 (vs JP¥65.91 in 3Q 2021)

C.I. Medical Co.,Ltd. (TSE:3540) agreed to acquire Naiki Shiken Ltd. from Yuichi Naiki and Yuriko Naiki.

C.I. Medical Co.,Ltd. to Report Q3, 2022 Results on Nov 08, 2022

C.I. Medical Co.,Ltd. (TSE:3540) agreed to acquire Sakura Dental Laboratory from Akira Ochi and Katsumi Ochi.

Second quarter 2022 earnings released: EPS: JP¥65.90 (vs JP¥67.61 in 2Q 2021)

C.I. Medical Co.,Ltd. to Report Q2, 2022 Results on Aug 09, 2022

First quarter 2022 earnings: EPS misses analyst expectations

Price target decreased to JP¥4,300

C.I. Medical Co.,Ltd. to Report Q1, 2022 Results on May 10, 2022

Investor sentiment improved over the past week

C.I. Medical Co.,Ltd., Annual General Meeting, Mar 24, 2022

Full year 2021 earnings: EPS misses analyst expectations

Now 22% undervalued after recent price drop

Now 20% undervalued after recent price drop

Price target decreased to JP¥5,300

Third quarter 2021 earnings released: EPS JP¥65.89 (vs JP¥81.10 in 3Q 2020)

Second quarter 2021 earnings released: EPS JP¥67.61 (vs JP¥65.10 in 2Q 2020)

Investor sentiment deteriorated over the past week

Looop Inc. agreed to acquire 60% stake in Niigata Prefectural Electric Power Co., Ltd. and Yotsuba Electric Power Co., Ltd. from C.I. Medical Co.,Ltd. (JASDAQ:3540).

Investor sentiment improved over the past week

First quarter 2021 earnings released: EPS JP¥87.40 (vs JP¥48.50 in 1Q 2020)

Here's Why We Think C.I. MedicalLtd (TYO:3540) Is Well Worth Watching

Returns on Capital Paint A Bright Future For C.I. MedicalLtd (TYO:3540)

Full year 2020 earnings released: EPS JP¥292 (vs JP¥151 in FY 2019)

Investor sentiment improved over the past week

Should You Investigate C.I. Medical Co.,Ltd. (TYO:3540) At JP¥5,450?

New 90-day low: JP¥5,490

Analysts increase EPS estimates to JP¥320

Introducing C.I. MedicalLtd (TYO:3540), The Stock That Zoomed 114% In The Last Year

C.I. Medical Co.,Ltd. (JASDAQ:3540) acquired 22.4% stake in Fuji Dental Lab Co., Ltd.

Full year 2020 earnings released: EPS JP¥292 (vs JP¥151 in FY 2019)

Revenue and earnings beat expectations

Should You Be Adding C.I. MedicalLtd (TYO:3540) To Your Watchlist Today?

Yosuke Oda Kaki and Keisuke Hori agreed to acquire an additional 60% stake in One Recto Holdings Co., Ltd. from C.I. Medical Co.,Ltd. (JASDAQ:3540).

New 90-day low: JP¥5,900

Can C.I. MedicalLtd (TYO:3540) Keep Up These Impressive Returns?

C.I. Medical Co.,Ltd. to Report Fiscal Year 2020 Results on Feb 21, 2021

Could The Market Be Wrong About C.I. Medical Co.,Ltd. (TYO:3540) Given Its Attractive Financial Prospects?

Upcoming Dividend of JP¥15.00 Per Share

New 90-day low: JP¥6,150